OMEROS CORP Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt
OMEROS CORP (OMER) reported Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt of -$22.07 million for the 12-month period ending 2020-12-31, per its 10-K filed 2023-03-13.
Discontinued › Shareholders' Equity › Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments
us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt · last filed 2023-03-13
- OMEROS CORP adjustments to additional paid in capital, equity component of convertible debt for the quarter ending 2020-09-30 was -$22.07M.
- OMEROS CORP adjustments to additional paid in capital, equity component of convertible debt for fiscal 2020 was -$22.07M.
- OMEROS CORP adjustments to additional paid in capital, equity component of convertible debt for fiscal 2018 was $55.66M.
| Period end | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 3 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 12 month |
|---|---|---|
| 2020-12-31 | -$22.07M 10-K · filed 2023-03-13 | |
| 2020-09-30 | -$22.07M 10-Q · filed 2021-11-09 | |
| 2018-12-31 | $55.66M 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |